GlassScriptPhysician profile
Benjamin Sirutis
NPI 1053844407
$12,220.59
in general payments reported to CMS, 2019-2025
34 companies · $3,006 in 2025
The $3,006 reported for 2025 was more than what 85% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.00 · 2022: $1,837 · 2023: $5,408 · 2024: $1,896 · 2025: $3,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,474 · Travel and Lodging: $3,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,473.95 |
| Travel and Lodging | $3,836.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,881.53 | 2023-2025 | Spinejack, Mild Device Kit, Optablate |
| Boston Scientific Corporation | $2,292.96 | 2022-2025 | Superion Indirect Decompression System, General - Pain Management, Intracept |
| Abbvie INC. | $1,671.71 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Relievant Medsystems, INC. | $1,651.47 | 2023 | Intracept |
| Medtronic, INC. | $1,039.93 | 2021-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Collegium Pharmaceutical, INC. | $444.87 | 2023-2025 | Belbuca |
| Nevro Corp. | $408.10 | 2022-2024 | Senza |
| Vertos Medical, INC. | $255.49 | 2023 | Mild Device Kit |
| Pfizer INC. | $193.02 | 2023-2025 | |
| Globus Medical, INC. | $164.10 | 2025 | Senza |
| Mml US, INC. | $162.30 | 2024-2025 | Reactiv8 |
| Foundation Fusion Solutions, LLC | $157.24 | 2025 | |
| Curonix LLC | $146.91 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spinal Simplicity, LLC | $115.02 | 2023-2025 | Ha Minuteman G3-R |
| Scilex Pharmaceuticals INC. | $74.44 | 2023 | Ztlido |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64.41 | 2024-2025 | Eterna |
| Merz Pharmaceuticals, LLC | $62.09 | 2023 | Xeomin |
| Lundbeck LLC | $53.17 | 2025 | Vyepti |
| Saluda Medical Americas, INC. | $43.61 | 2024-2025 | Evoke |
| Averitas Pharma INC. | $38.25 | 2023 | Qutenza |
| Stimwave Technologies Incorporated | $34.08 | 2022 | |
| Lilly USA, LLC | $29.49 | 2022-2023 | Emgality |
| Si-Bone, INC. | $29.23 | 2022 | |
| Forte Bio-Pharma LLC | $26.80 | 2024 | Prolate, Nalocet |
| Djo, LLC | $25.05 | 2025 | Cmf |
| Nalu Medical, INC. | $21.41 | 2025 | Nalu Neurostimulation System |
| Paratek Pharmaceuticals, INC. | $19.92 | 2022 | |
| Painteq LLC | $19.05 | 2024 | Painteq |
| Spr Therapeutics, INC | $18.04 | 2024 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.63 | 2024 | Relistor |
| Valinor Pharma, LLC | $17.18 | 2025 | Movantik |
| Avanos Medical | $15.72 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.26 | 2022 | |
| Fidia Pharma USA INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Sirutis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.